Hims & Hers Health, Inc. investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beat ...

Deutsche Bank analyst George Hill raised the firm’s price target on Hims & Hers to $27 from $23 and keeps a Hold rating on the shares ...

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

Most investors would look at an earnings announcement as a past event, connecting the current price action in the stock and reacting to the results as something that cannot be taken advantage of, ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 830% — a ...

Bank of America Securities analyst Allen Lutz reiterated a Sell rating on Henry Schein (HSIC – Research Report) today. The ...

Headlines,Hims & Hers Health Surpasses Earnings Expectations,Strong Revenue Growth Drives Positive Stock Movement,Analysts ...

Tropical Storm Rafael, which is expected to strengthen and may hit the Gulf Coast later this week, could further disrupt the IV solution supply chain if its path shifts towards Texas, where 4.4% of U.

December S&P 500 E-Mini futures (ESZ24) are down -0.02%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.10% this morning as market participants awaited the outcome of one of the most ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update ...